Home > Oncology > SABCS 2019 > Phase 2 Trial Update > Residual cancer burden is a predictor for all-type breast cancer patients

Residual cancer burden is a predictor for all-type breast cancer patients

Conference
SABCS 2019

Residual cancer burden (RCB) after neoadjuvant chemotherapy has shown to be an accurate long-term predictor of recurrence and survival across all breast cancer subtypes, as demonstrated by a large meta-analysis of breast cancer patients.

RCB is assessed through several factors, including the size of the primary tumour, the percentage of the tumour which is invasive versus in situ, and the involvement of lymph nodes. Although many single-institution studies have shown that RCB after neoadjuvant chemotherapy is informative about a patient’s prognosis after surgery, a meta-analysis was done to help determine whether this is true for all subtypes, and how generalisable previous findings might be [1]. Data from 12 cancer centres or clinical trials representing approximately 5,100 patients were compiled and analysed in this study. Using mixed effect models, associations between the RCB index and event-free survival (EFS) and distant recurrence-free survival (DRF...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on